Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial Jan 19, 2022
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product Jan 14, 2022
How Significant Are Recent Changes To Psychedelics Access In Canada? ‘It Can’t Be Understated’ Says Numinus CEO Jan 12, 2022